PreveCeutical Medical and BioGene Therapeutics Announce Closing of Plan of Arrangement

Core Viewpoint - PreveCeutical Medical Inc. and BioGene Therapeutics Inc. have successfully completed a plan of arrangement involving the spin-off of 12,000,000 shares of BioGene from PreveCeutical, effective November 25, 2025 [2][3]. Group 1: Arrangement Details - The plan of arrangement was approved by PreveCeutical's shareholders during the annual general and special meeting on October 10, 2025, and received final approval from the Supreme Court of British Columbia on October 17, 2025 [3]. - PreveCeutical underwent a share capital reorganization, renaming existing common shares as Class A common shares and creating a new class of voting common shares [4]. - Shareholders received one New PreveCeutical Share and 0.02 BioGene Spinout Shares for each PreveCeutical Share held as of November 25, 2025 [4]. Group 2: Company Focus - PreveCeutical is a health sciences company focused on developing innovative preventive and curative therapies using organic and nature identical products [5]. - The company has five research and development programs, including dual gene therapy for diabetes and obesity, Sol-gel Program, Nature Identical™ peptides for various ailments, non-addictive analgesic peptides, and a therapeutic product for athletes with concussions [5].